1. Malaysia Stocks

  2. •

    Distribution services

  3. •

    Medical distributors
Pharmaniaga Bhd.

Pharmaniaga Bhd.

MMYX:PHARMA
0.81
MYR
+0.03
(+3.18%)
14.63P/E
Nov 13Next Earn
Pharmaniaga Bhd.
MYX:PHARMA
(Bursa Malaysia)

Recent

price

0.81

P/E

ratio

14.63

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
MYR
3.16
3.49
4.16
4.47
4.88
5.03
5.02
5.32
5.45
6.43
6.2
10.93
7.9
7.4
7.75
5.43
5.55
Revenue per Share
0.07
0.12
0.14
0.13
0.22
0.19
0.1
0.12
0.1
-0.34
0.06
0.39
-1.43
-0.17
0.27
0.07
0.08
Basic EPS, GAAP
-0.02
-0.1
-0.18
-0.18
-0.2
-0.27
-0.26
-0.18
-0.16
-0.17
-0.07
-0.1
-0.18
-0.16
-0.08
-0.05
-0.14
Free Cash Flow per Basic Share
0.09
- -
0.14
0.09
0.13
0.21
0.12
0.1
0.09
0.09
0.06
0.13
0.19
0.02
- -
- -
- -
Dividend per Share
0.97
1.07
1.08
1.12
1.21
1.22
1.22
1.21
1.16
0.77
0.77
1.02
-0.84
-0.62
-0.35
0.33
0.35
Book Value per Share
0.9
0.83
0.74
0.83
0.67
0.56
0.42
0.37
0.24
0.31
0.3
0.55
-1.2
-0.93
-0.67
0.22
0.23
Tangible Book Value per Share
435
435
435
435
435
435
436
437
438
439
440
440
441
460
485
723
750
Basic Weighted Avg Shares
1,374
1,521
1,812
1,947
2,123
2,189
2,189
2,324
2,385
2,821
2,725
4,815
3,481
3,404
3,759
3,928
4,165
Sales/Revenue/Turnover
6.03
4.91
6.46
5.44
6.61
5.78
4.73
4.31
4.39
-5.46
2.49
6.39
-15.05
-0.59
6.94
3.3
3.04
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
30
52
62
55
94
84
46
54
42
-149
27
172
-630
-80
132
49
59
Net Income, GAAP
33.33
27.88
38.82
38.96
24.97
24.96
36.32
24.6
38.44
- -
26.61
37.85
- -
- -
31.1
32.18
28.58
Effective Tax Rate (%)
2.21
3.43
3.4
2.84
4.42
3.84
2.08
2.32
1.78
-5.29
1.01
3.58
-18.1
-2.35
3.51
1.24
1.41
Profit Margin (%)
117
29
- -
25
-51
-125
-185
-214
-248
-267
-268
153
-873
-895
-749
-147
16
Working Capital
- -
- -
- -
- -
1
1
- -
- -
- -
2
1
286
97
140
133
126
299
LT Debt
437
482
488
503
552
560
559
547
529
357
355
470
-348
-274
-146
459
483
Total Equity
11.26
9.5
9.64
8.57
14.72
11.17
6.2
7.01
6
- -
5.17
16.33
- -
- -
18.33
7.54
7.74
Return on Invested Capital (%)
11.1
9.57
9.26
8.17
14.56
11.07
6.25
6.85
5.91
- -
5.47
16.38
- -
- -
18.28
7.56
7.8
Return on Capital (%)
7.13
11.75
13.16
11.5
18.51
15.92
8.6
10.17
8.19
-35.23
8.14
43.69
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

MYR

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
694
690
482
LT Borrowings
125
110
299
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,311
1,311
1,311
Market Capitalization
1,862
1,613
1,508

Working Capital

MYR

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
1,464
1,566
1,652
Cash, Cash Equivalents & STI
259
217
152
Accounts Receivable, Net
447
672
734
Inventories
730
666
758
Total Current Liabilities
1,611
1,707
1,636
Payables & Accruals
- -
- -
- -
ST Debt
694
690
482
Deferred Revenue
- -
- -
- -

Growth Rates

MYR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-66.29%
-124.84%
-414.61%
Free Cash Flow
-4.03%
11.29%
-2.27%
Net Income, GAAP
-97.32%
-70.92%
-63.2%
Sales/Revenue/Turnover
8.53%
12.34%
4.48%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

MYR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
965
838
1,030
926
3,759
2025
1,055
927
1,007
938
3,928
2026
1,179
1,041
- -
- -
- -

Quarterly Earnings Per Share

MYR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.05
0.01
0.21
- -
0.27
2025
0.06
0.01
0.01
0.01
0.07
2026
0.02
0.03
- -
- -
- -

Quarterly Dividends Per Share

MYR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
DataMeds AI, Inc. (NASDAQ:MEDS)
Selcuk Ecza Deposu Ticaret ve Sanayi A.S. (BIST:SELEC)
McKesson Corporation (NYSE:MCK)
Ibnsina Pharma (EGX:ISPH)
Cardinal Health, Inc. (NYSE:CAH)
Entero Healthcare Solutions Limited (NSE:ENTERO)
Business
Pharmaniaga Berhad operates as a prominent investment holding enterprise, functioning as a fully integrated provider of healthcare solutions across Malaysia, Indonesia, and various international territories. The company organizes its comprehensive operations into key divisions: Logistics and Distribution, Manufacturing, and its Indonesia segment. Its diverse activities encompass the development, production, storage, wholesaling, and marketing of an extensive portfolio of pharmaceutical and medical goods. Additionally, Pharmaniaga engages in the procurement, delivery, and installation of specialized medical and hospital equipment. The group's manufacturing capabilities span generic medications, consumer health products, and nutritional supplements, bolstered by continuous research and development efforts in pharmaceutical innovations. They also facilitate the distribution of diagnostic products and implement advanced pharmacy management systems. Founded in Shah Alam, Malaysia, in 1994, Pharmaniaga, a subsidiary of Boustead Holdings Berhad, has recently demonstrated a significant financial turnaround and is strategically advancing its biopharmaceutical capabilities, including the establishment of halal vaccine and insulin production facilities, aiming for market leadership and national self-reliance in vital healthcare products.